Built Or Bought? Why Biotechs Are Outsourcing Supply Chain Infrastructure

For biotechs developing Advanced Therapy Medicinal Products (ATMPs), the decision to "build or buy" supply chain infrastructure is a critical strategic consideration. Building an in-house end-to-end logistics network demands significant upfront capital expenditure, extensive lead times, and highly specialized personnel to manage the inherent complexities of the cold chain and regulatory compliance.

The accelerating trend toward outsourcing converts this fixed CapEx burden into a flexible operating model. Partnering with a specialized supply chain provider grants immediate access to a pre-validated global network, essential regulatory expertise, and purpose-built systems. This approach not only frees up valuable capital for R&D and clinical milestones but also serves as a proactive risk mitigation strategy, enabling flexible scale-up and global expansion without the internal burden of managing geopolitical and regulatory flux. Discover how strategic outsourcing can de-risk your clinical plans and accelerate your path to commercialization.